A dosimetric evaluation of ureteric doses with and without ureter as avoidance organ in patients treated with MR hybrid brachytherapy for cervical cancer
Brachytherapy · 2025-07 · 24 (4) · 504-509
DOI: 10.1016/j.brachy.2025.02.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2025-07. Verfasst von Harjot Kaur Bajwa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, American Oncology Institute, Hyderabad, Telangana, India. Electronic address: harjotbajwa1987@gmail.com. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Brachytherapy, Ureter. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Ureteric stenosis is a known complication with radiotherapy with studies showing correlation of ureteric dose with stenosis. This study was done to assess the dose delivered to the ureters with and without ureter as avoidance organ in cervical cancer patients treated with hybrid brachytherapy. MATERIAL AND METHODS: Cervical cancer patients treated with EBRT and MR hybrid brachytherapy were retrospectively analyzed. They were treated without ureter contoured as organ at risk. The right and left ureters were retrospectively contoured on T2 weighted MRI images. Dose to 0.1cc volume of ureter was documented. RESULTS: 26 patients treated with hybrid brachytherapy were analyzed. The median HRCTV volume was 23.9cc. The median HRCTV D90 & GTV D98 EQD2 were 91.09Gy (IQR 92.36-87.28) and 104.67Gy (IQR 113.90-95.04) respectively. The median D2cc for bladder, rectum and sigmoid were 75.46Gy, 58.10Gy and 61.3Gy EQD2 respectively. The mean minimum distance of the left ureter from HRCTV was 3.2mm (IQR 6.75-1) & right ureter was 2.3mm (IQR 8-0). The mean D0.1cc to the left ureter was 75.16Gy EQD2 (IQR 88.28-58.20) and to the right ureter was 69.73Gy EQD2 (IQR 76.77-56.01). The ureter D0.1cc exceeded 77Gy in 13/26 patients. Replanning and reducing needle loading near the ureter resulted in reduction of ureter 0.1cc dose to less than 77Gy in all but 2 patients, without compromising the HRCTV coverage. CONCLUSION: The ureter is at risk of receiving high doses when we use hybrid applicator. MR planning to delineate the ureter and careful optimization of needles can result in significant reduction of ureter dose with similar target coverage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, American Oncology Institute, Hyderabad, Telangana, India. Electronic address: harjotbajwa1987@gmail.com.
- Medical Affairs, Varian Medical Systems, Inc., Palo Alto, CA; Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA.
- Department of Radiation Oncology, American Oncology Institute, Hyderabad, Telangana, India.
- Department of Radiation Physics, American Oncology Institute, Hyderabad, Telangana, India.
Zitieren
APA
Bajwa, H. K., Beriwal, S., Natte, R., Kumar, R. C., Kumar, R., & Chaudhari, S. (2025). A dosimetric evaluation of ureteric doses with and without ureter as avoidance organ in patients treated with MR hybrid brachytherapy for cervical cancer. Brachytherapy, 24(4), 504-509. https://doi.org/10.1016/j.brachy.2025.02.007
Vancouver
Bajwa HK, Beriwal S, Natte R, Kumar RC, Kumar R, Chaudhari S. A dosimetric evaluation of ureteric doses with and without ureter as avoidance organ in patients treated with MR hybrid brachytherapy for cervical cancer. Brachytherapy. 2025;24(4):504-509. doi:10.1016/j.brachy.2025.02.007
BibTeX
@article{Bajwa2025,
author = {Bajwa, Harjot Kaur and Beriwal, Sushil and Natte, Rajesh and Kumar, Racharla Chandra and Kumar, Rampally and Chaudhari, Suresh},
title = {A dosimetric evaluation of ureteric doses with and without ureter as avoidance organ in patients treated with MR hybrid brachytherapy for cervical cancer},
journal = {Brachytherapy},
year = {2025},
volume = {24},
number = {4},
pages = {504--509},
doi = {10.1016/j.brachy.2025.02.007}
}
EUVIMED